drugset / Trial / NCT06724926
Concurrent Azeliragon With Craniospinal Irradiation
NaSingle-groupOpen-labelTreatment
Summary
Single institution study to assess the safety of concurrent Azeliragon with craniospinal irradiation (CSI) in patients with leptomeningeal metastasis from solid tumor malignancies and high-grade gliomas.
Timeline
- Start
- 2025-02-18
- Primary completion
- 2027-01
- Completion
- 2031-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azeliragon | Small molecule | 5 mg | Oral |
| Subject | Azeliragon | Small molecule | 10 mg | Oral |
| Subject | Azeliragon | Small molecule | 20 mg | Oral |